Physician profile
George Gonzalez
NPI 1619029287
$5,889.18
in general payments reported to CMS, 2019-2025
36 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.08 · 2020: $141 · 2021: $999 · 2022: $577 · 2023: $1,240 · 2024: $1,220 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,110.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,576.85 | 2021-2025 | |
| Biogen, INC. | $481.05 | 2020-2025 | Vumerity, Tysabri, Skyclarys |
| Ge Healthcare | $456.78 | 2021-2025 | |
| Pfizer INC. | $409.90 | 2023-2025 | |
| Eisai INC. | $283.96 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $269.93 | 2021-2025 | Ultomiris |
| Argenx US, INC. | $249.42 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Impel Pharmaceuticals INC. | $190.24 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $168.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $163.48 | 2019-2025 | Austedo Xr |
| Ucb, INC. | $152.74 | 2023-2024 | Rystiggo |
| Biohaven Pharmaceutical Holding Company LTD. | $150.17 | 2022 | |
| Boston Scientific Corporation | $145.56 | 2021 | |
| Amneal Pharmaceuticals LLC | $130.42 | 2021-2024 | Rytary |
| Mdd US Operations, LLC | $126.87 | 2020-2025 | Apokyn |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $97.07 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $90.79 | 2021-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $82.43 | 2021-2025 | Wainua |
| Takeda Pharmaceuticals U.S.A., INC. | $81.97 | 2024-2025 | Hyqvia |
| Lilly USA, LLC | $71.16 | 2024-2025 | Kisunla |
| Neurelis, INC. | $64.50 | 2020-2022 | |
| Axsome Therapeutics, INC. | $63.57 | 2025 | Symbravo |
| Janssen Biotech, INC. | $54.28 | 2025 | |
| Acadia Pharmaceuticals INC | $46.47 | 2023-2024 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $43.23 | 2025 | |
| Tg Therapeutics, INC. | $29.87 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $25.50 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $24.34 | 2019 | |
| Emd Serono, INC. | $24.24 | 2023 | Mavenclad |
| Neurocrine Biosciences, INC. | $21.56 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.20 | 2021 | |
| Sk Life Science, INC. | $20.28 | 2024 | |
| Currax Pharmaceuticals LLC | $19.80 | 2020 | |
| Idorsia Pharmaceuticals US INC | $19.48 | 2023 | Quviviq |
| Kyowa Kirin, INC. | $16.36 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.